Sign in Sign up for free

Last updated: 2 July 2019 at 2:23am EST

Mitchell J Kelly Net Worth




The estimated Net Worth of Mitchell J Kelly is at least $10.1 Million dollars as of 2 March 2006. Mitchell Kelly owns over 1,739,601 units of Novavax stock worth over $6,145 and over the last 22 years Mitchell sold NVAX stock worth over $10,130,645.

Mitchell Kelly NVAX stock SEC Form 4 insiders trading

Mitchell has made over 4 trades of the Novavax stock since 2004, according to the Form 4 filled with the SEC. Most recently Mitchell sold 1,739,601 units of NVAX stock worth $9,393,845 on 2 March 2006.

The largest trade Mitchell's ever made was selling 1,739,601 units of Novavax stock on 2 March 2006 worth over $9,393,845. On average, Mitchell trades about 262,450 units every 55 days since 2003. As of 2 March 2006 Mitchell still owns at least 500 units of Novavax stock.

You can see the complete history of Mitchell Kelly stock trades at the bottom of the page.



What's Mitchell Kelly's mailing address?

Mitchell's mailing address filed with the SEC is , , , , .

Insiders trading at Novavax

Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi, and Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.



What does Novavax do?

novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"​), seasonal influenza, pandemic influenza, and ebola virus ("ebov"​). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.



What does Novavax's logo look like?

Novavax, Inc. logo

Complete history of Mitchell Kelly stock trades at Novavax

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
2 Mar 2006 NVAX Novavax, Inc. Mitchell J Kelly
Director
 Sale 1,739,601 $5.40 $9,393,845
2 Mar 2006
500 ↗
9 Sep 2005 NVAX Novavax, Inc. Mitchell J Kelly
Director
 Sale 260,000 $1.57 $408,200
9 Sep 2005
1,740,101 ↗
28 Dec 2004 NVAX Novavax, Inc. Mitchell J Kelly
Director
 Sale 60,000 $3.27 $196,200
28 Dec 2004
2,000,101 ↗
20 Dec 2004 NVAX Novavax, Inc. Mitchell J Kelly
Director
 Sale 40,000 $3.31 $132,400
20 Dec 2004
95,000 ↗


Novavax executives and stock owners

Novavax executives and other stock owners filed with the SEC include: